| | | |
Per Share
|
| |
Total
|
| ||||||
|
Public offering price(1)
|
| | |
US$
|
9.250
|
| | | |
US$
|
153,000,004
|
| |
|
Underwriting discounts and commissions(2)
|
| | |
US$
|
0.555
|
| | | |
US$
|
9,180,000
|
| |
|
Proceeds to BELLUS Health Inc. (before expenses)
|
| | |
US$
|
8.695
|
| | | |
US$
|
143,820,004
|
| |
| Jefferies | | |
Evercore ISI
|
| |
RBC Capital Markets
|
|
|
UNDERWRITERS’ POSITION
|
| |
MAXIMUM SIZE
|
| |
EXERCISE PERIOD
|
| |
EXERCISE PRICE
|
|
| Option to purchase additional common shares | | | 2,481,081 common shares | | | 30 days after the date of this prospectus supplement | | | US$9.25 per common share | |
|
TABLE OF CONTENTS
|
| | | | | | |
|
PROSPECTUS SUPPLEMENT
|
| | |||||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| CAPITALIZATION | | | |
|
| | |
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| UNDERWRITING | | | |
|
| | |
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| |
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| |
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| |
DOSE
|
| |
PLACEBO-ADJUSTED
CHANGE IN 24-HOUR COUGH FREQUENCY AT DAY 28 |
| |
P-VALUE
|
| ||||||
12.5 mg BID
|
| | |
|
-21.1%
|
| | | |
|
p=0.098
|
| |
50 mg BID
|
| | |
|
-34.4%
|
| | | |
|
p=0.003
|
| |
200 mg BID
|
| | |
|
-34.2%
|
| | | |
|
p=0.005
|
| |
DOSE
|
| |
PLACEBO-ADJUSTED
REDUCTION IN AWAKE COUGH FREQUENCY |
| |
P-VALUE
|
| ||||||
25 mg BID
|
| | |
|
-11%
|
| | | |
|
p=0.14
|
| |
50 mg BID
|
| | |
|
-6%
|
| | | |
|
p=0.46
|
| |
100 mg BID
|
| | |
|
-8%
|
| | | |
|
p=0.41
|
| |
200 mg BID
|
| | |
|
-17%
|
| | | |
|
p=0.09
|
| |
DOSE
|
| |
PLACEBO-ADJUSTED
REDUCTION IN AWAKE COUGH FREQUENCY |
| |
P-VALUE
|
| ||||||
25 mg BID
|
| | |
|
-20%
|
| | | |
|
p=0.0010
|
| |
50 mg BID
|
| | |
|
-18%
|
| | | |
|
p=0.0186
|
| |
100 mg BID
|
| | |
|
-19%
|
| | | |
|
p=0.0320
|
| |
200 mg BID
|
| | |
|
-27%
|
| | | |
|
p=0.0026
|
| |
DOSE
|
| |
PLACEBO-ADJUSTED
REDUCTION IN AWAKE COUGH FREQUENCY |
| |
P-VALUE
|
| ||||||
25 mg BID
|
| | |
|
-28%
|
| | | |
|
p=0.0005
|
| |
50 mg BID
|
| | |
|
-28%
|
| | | |
|
p=0.0003
|
| |
100 mg BID
|
| | |
|
-30%
|
| | | |
|
p=0.0014
|
| |
200 mg BID
|
| | |
|
-32%
|
| | | |
|
p=0.0006
|
| |
PURPOSE
|
| |
ESTIMATED AMOUNT
|
|
BLU-5937 clinical trials in chronic cough
|
| |
US$ 82.0 million
|
|
Manufacturing, formulation and scale-up
|
| |
US$29.7 million
|
|
Other project costs
|
| |
US$18.0 million
|
|
Working capital and general administration
|
| |
US$13.2 million
|
|
| | |
AS OF MARCH 31, 2022
|
| |||||||||
| | |
ACTUAL
|
| |
AS ADJUSTED
|
| ||||||
| | |
(UNAUDITED)
(IN THOUSANDS OF US$) |
| |||||||||
Cash and cash equivalents
|
| | |
$
|
147,155
|
| | | |
$
|
290,052
|
| |
Short-term investments
|
| | |
|
86,813
|
| | | |
|
86,813
|
| |
Total
|
| | |
$
|
233,968
|
| | | |
$
|
376,865
|
| |
Shareholders’ Equity | | | | | | | | | | | | | |
Share capital (outstanding common shares – 106,744,431; as
adjusted – 123,284,972) |
| | |
$
|
800,015
|
| | | |
$
|
953,015
|
| |
Other equity
|
| | |
|
39,156
|
| | | |
|
39,156
|
| |
Deficit
|
| | |
|
(568,676)
|
| | | |
|
(578,779)
|
| |
Accumulated other comprehensive income
|
| | |
|
9,298
|
| | | |
|
9,298
|
| |
Total shareholders’ equity
|
| | |
|
279,793
|
| | | |
|
422,690
|
| |
Total capitalization
|
| | |
$
|
279,793
|
| | | |
$
|
422,690
|
| |
|
DATE OF GRANT
|
| |
NUMBER OF
OPTIONS ISSUED |
| |
EXERCISE PRICE
(PER OPTION) |
|
August 11, 2021
|
| |
20,000
|
| |
US$3.10
|
|
November 10, 2021
|
| |
180,000
|
| |
US$7.04
|
|
February 23, 2022
|
| |
2,945,000
|
| |
US$7.01
|
|
March 23, 2022
|
| |
390,000
|
| |
US$6.38
|
|
May 11, 2022
|
| |
220,000
|
| |
US$7.85
|
|
July 6, 2022
|
| |
200,000
|
| |
US$9.58
|
|
DATE OF ISSUANCE
|
| |
NUMBER OF
SHARES ISSUED |
| |
EXERCISE PRICE
(PER OPTION OR SHARE, AS APPLICABLE) |
|
November 4, 2021
|
| |
888
|
| |
Cdn$1.80
|
|
November 4, 2021
|
| |
7,778
|
| |
Cdn$1.08
|
|
November 8, 2021
|
| |
7,000
|
| |
Cdn$1.80
|
|
December 14, 2021
|
| |
25,000,000
|
| |
US$8.00
|
|
December 23, 2021
|
| |
33,334
|
| |
Cdn$1.08
|
|
December 23, 2021
|
| |
4,000
|
| |
Cdn$3.14
|
|
December 29, 2021
|
| |
3,000,000
|
| |
US$8.00
|
|
January 10, 2022
|
| |
4,111
|
| |
Cdn$1.80
|
|
January 11, 2022
|
| |
3,000
|
| |
Cdn$1.80
|
|
February 17, 2022
|
| |
5,667
|
| |
Cdn$3.78
|
|
March 1, 2022
|
| |
118,520
|
| |
Cdn$1.80
|
|
March 1, 2022
|
| |
86,720
|
| |
Cdn$1.80
|
|
March 3, 2022
|
| |
20,833
|
| |
Cdn$1.80
|
|
March 3, 2022
|
| |
11,111
|
| |
Cdn$1.08
|
|
March 3, 2022
|
| |
16,666
|
| |
Cdn$1.26
|
|
March 22, 2022
|
| |
87,442
|
| |
Cdn$1.80
|
|
April 8, 2022
|
| |
2,072
|
| |
Cdn$3.14
|
|
April 19, 2022
|
| |
1,301
|
| |
Cdn$3.58
|
|
May 20, 2022
|
| |
23,490
|
| |
Cdn$1.26
|
|
| | |
TSX
|
| |
NASDAQ COMPOSITE
|
| ||||||||||||||||||||||||||||||
| | |
HIGH
|
| |
LOW
|
| |
VOLUME
|
| |
HIGH
|
| |
LOW
|
| |
VOLUME
|
| ||||||||||||||||||
| | |
(CDN$)
|
| |
(CDN$)
|
| |
(#)
|
| |
(US$)
|
| |
(US$)
|
| |
(#)
|
| ||||||||||||||||||
July 2021
|
| | |
|
4.00
|
| | | |
|
3.32
|
| | | |
|
689,987
|
| | | |
|
3.22
|
| | | |
|
2.60
|
| | | |
|
10,274,074
|
| |
August 2021
|
| | |
|
4.82
|
| | | |
|
3.54
|
| | | |
|
852,624
|
| | | |
|
3.83
|
| | | |
|
2.82
|
| | | |
|
10,059,420
|
| |
September 2021
|
| | |
|
9.31
|
| | | |
|
4.42
|
| | | |
|
6,012,205
|
| | | |
|
7.35
|
| | | |
|
3.50
|
| | | |
|
115,635,428
|
| |
October 2021
|
| | |
|
9.25
|
| | | |
|
7.10
|
| | | |
|
2,171,242
|
| | | |
|
7.48
|
| | | |
|
5.68
|
| | | |
|
16,812,714
|
| |
November 2021
|
| | |
|
9.47
|
| | | |
|
6.91
|
| | | |
|
1,701,319
|
| | | |
|
7.65
|
| | | |
|
5.41
|
| | | |
|
23,184,217
|
| |
December 2021
|
| | |
|
12.59
|
| | | |
|
6.64
|
| | | |
|
3,968,455
|
| | | |
|
9.84
|
| | | |
|
5.18
|
| | | |
|
153,383,543
|
| |
January 2022
|
| | |
|
10.55
|
| | | |
|
6.30
|
| | | |
|
2,775,604
|
| | | |
|
8.21
|
| | | |
|
4.98
|
| | | |
|
22,294,330
|
| |
February 2022
|
| | |
|
9.40
|
| | | |
|
7.23
|
| | | |
|
2,357,964
|
| | | |
|
7.45
|
| | | |
|
5.61
|
| | | |
|
28,447,599
|
| |
March 2022
|
| | |
|
8.85
|
| | | |
|
7.00
|
| | | |
|
1,601,946
|
| | | |
|
7.11
|
| | | |
|
5.45
|
| | | |
|
10,156,932
|
| |
April 2022
|
| | |
|
11.29
|
| | | |
|
8.46
|
| | | |
|
2,040,624
|
| | | |
|
9.04
|
| | | |
|
6.76
|
| | | |
|
17,818,288
|
| |
May 2022
|
| | |
|
11.68
|
| | | |
|
8.07
|
| | | |
|
3,830,869
|
| | | |
|
9.09
|
| | | |
|
6.35
|
| | | |
|
17,888,269
|
| |
June 2022
|
| | |
|
13.25
|
| | | |
|
9.18
|
| | | |
|
2,040,276
|
| | | |
|
10.28
|
| | | |
|
7.08
|
| | | |
|
19,689,433
|
| |
July 2022 (to July 13)
|
| | |
|
14.46
|
| | | |
|
11.61
|
| | | |
|
1,383,789
|
| | | |
|
11.10
|
| | | |
|
8.82
|
| | | |
|
9,783,208
|
| |
UNDERWRITER
|
| |
NUMBER
OF COMMON SHARES |
| |||
Jefferies LLC
|
| | |
|
6,616,217
|
| |
Evercore Group L.L.C.
|
| | |
|
4,962,163
|
| |
RBC Capital Markets, LLC
|
| | |
|
2,811,891
|
| |
LifeSci Capital LLC
|
| | |
|
2,150,270
|
| |
Total
|
| | |
|
16,540,541
|
| |
|
| | |
PER SHARE
|
| |
TOTAL
|
| ||||||
| | |
WITHOUT
OPTION TO PURCHASE ADDITIONAL SHARES |
| |
WITH
OPTION TO PURCHASE ADDITIONAL SHARES |
| |
WITHOUT
OPTION TO PURCHASE ADDITIONAL SHARES |
| |
WITH
OPTION TO PURCHASE ADDITIONAL SHARES |
|
Public offering
price |
| | US$9.250 | | | US$9.250 | | | US$153,000,004 | | | US$175,950,004 | |
Underwriting discounts and commissions paid by us | | | US$0.555 | | | US$0.555 | | | US$ 9,180,000 | | | US$ 10,557,001 | |
Proceeds to us, before expenses
|
| | US$8.695 | | | US$8.695 | | | US$143,820,004 | | | US$165,393,003 | |
|
(Signed) ROBERTO BELLINI
President and Chief Executive Officer |
| |
(Signed) RAMZI BENAMAR
Chief Financial Officer |
|
|
(Signed) DR FRANCESCO BELLINI
Director |
| |
(Signed) PIERRE LAROCHELLE
Director |
|
| | | | | 1 | | | |
| | | | | 2 | | | |
| | | | | 2 | | | |
| | | | | 4 | | | |
| | | | | 6 | | | |
| | | | | 7 | | | |
| | | | | 10 | | | |
| | | | | 10 | | | |
| | | | | 12 | | | |
| | | | | 19 | | | |
| | | | | 20 | | | |
| | | | | 21 | | | |
| | | | | 22 | | | |
| | | | | 23 | | | |
| | | | | 24 | | | |
| | | | | 28 | | | |
| | | | | 34 | | | |
| | | | | 35 | | | |
| | | | | 35 | | | |
| | | | | 35 | | | |
| | | | | 36 | | | |
| | | | | 58 | | | |
| | | | | 58 | | | |
| | | | | 58 | | | |
| | | | | 58 | | | |
| | | | | 60 | | |
Dose
|
| |
Placebo-adjusted
reduction in awake cough frequency |
| |
P-value
|
| ||||||
25mg BID
|
| | | | -11% | | | | | | p=0.14 | | |
50mg BID
|
| | | | -6% | | | | | | p=0.46 | | |
100mg BID
|
| | | | -8% | | | | | | p=0.41 | | |
200mg BID
|
| | | | -17% | | | | | | p=0.09 | | |
Dose
|
| |
Placebo-adjusted
reduction in awake cough frequency |
| |
P-value
|
| ||||||
25mg BID
|
| | | | -20% | | | | | | p=0.0010 | | |
50mg BID
|
| | | | -18% | | | | | | p=0.0186 | | |
100mg BID
|
| | | | -19% | | | | | | p=0.0320 | | |
200mg BID
|
| | | | -27% | | | | | | p=0.0026 | | |
Dose
|
| |
Placebo-adjusted
reduction in awake cough frequency |
| |
P-value
|
| ||||||
25mg BID
|
| | | | -28% | | | | | | p=0.0005 | | |
50mg BID
|
| | | | -28% | | | | | | p=0.0003 | | |
100mg BID
|
| | | | -30% | | | | | | p=0.0014 | | |
200mg BID
|
| | | | -32% | | | | | | p=0.0006 | | |
|
(Signed) Roberto Bellini
President and Chief Executive Officer |
| |
(Signed) ramzi benamar
Chief Financial Officer |
|
|
(Signed) Dr Francesco Bellini
Director |
| |
(Signed) Pierre Larochelle
Director |
|
Z/2/B\?O8 G A Y^#+X<"S5DX$& &(#V]W=22:G-U;,%"$4T,JX5(!R
M;2 $:BD82;IUU-1,@]BW+V DSQ%1NTBJQZK
M84C*%.02G23,2(55K)H.\MQK9M#,:*J!");#4L'6)"+P=.S1F]3TVD^;PTNQ
M5G8B358.$&LDNF? 3]M#H>1%2;2R*>G1<=X:@1GX$6,^D5Q]YU4[-^EU51:IV*BHV
MNK-@'MQ=V)VD[F?496'R/'E3Z.X]7^K0=M#UCQ^8&%_C/[-_5'MQ=V'VE+F?
M496'R/%\G<>;O!VT/6'F!A?XS^S?U1[<7=A]I2YOU&5A\CQ/)W'F[P=M#UAY
M@87^,_LW]4@>>+NQ/!S*7,^&QM8?(L/)['F[P=M#UAY@87^._LW^HGVXN[$[
M2ES/J,K#Y'AY.X]W:#MH>L/,#"_QG]F_JDASQ]V&'^LI G;]!M8".T! =O"9[0'#R=QYN\';0
M]8>8&%_C/[)_5'MQ]V)VD[FC_P!AE8[ \ !DSV%#P &P,@\08>3N.]V@[:%K
M%\P,,?&?V;^J1[<7=B=I.YOU&5A\CP\G<>[M!VT/6''^&/C/[-_5'MQ=V)VE
M+F_496'R/#R=Q[NT+;0]8GF!ACXS^S?U1[<7=B=I2YGU&5A\CQ?)W'N[0=M#
MUAY@87^,_LW]4>W%W8G:3N9]1E8?(L/)W'F[P=M#UB^8&%_C/[-_5'MQ=V)V
ME+F?496'R+$\GL>;M!VT/6'F!A?XS^S?U3(J8[P#NQJ>?O7J?,9L7S PO\ &?V;^J/;
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M\CP\GL>;M"VT/6'F!A?XS^S?U1[=B=I.YGU&UA\BP\GL>;M"VT/6+Y@87^
M,_LW^H>W%W8G:4N9]1M7_(\/)['F[P=M#UB>8&%_C/[-_5'MQ=V'VE+F?496
M'R/#R=QYNT';0M8>8&%_C/[-_5'MQ=V'VE+F?496'R/#R=QYNT';0M8>8&%_
MC/[-_5,QE.\+[LB0HJDJ2'F,N&1.FY6JI(BY+)5P9VL:HBP(* NB>+(V(DD6
M(#=B14YAS-J NS//D[CQO]&AK[LTQ0C?"X2="PUMEW-)2E'TV
MRGX^GF,_;6V=2R,"WJE\[E)[J2I)^D9&IHA=[)/#K;]N\3634*02&)NT]*
^< ^DNFDF2FDX(VI9N%BZDA8U
MZ#>,JV.9Q50M^':+C(Q\?-QM0M6PJKHJKMA3EHANKK0.DH8$]&L"&.!E392^
M]!*4LRS-,ZG[Y74JA^_E)^KG,J^DJ :6N>K.HZ&S5H1BNU=MX!(I(XJ;4I7C
M%-8SA($W2JHG.=4QE%-27,5,M?MES%"EYZ\O9JE5JI:(5>>2JFK:B@5UY &;VGF+!FPZOAB':MG30^Y\]OU5@5T &:4J^7
M.7ZFGE#5+4-$T_'1U*2$<[G+6"T@FU&'3JE*9-+1I+@+U/.C")MY"GG1SR(B
MT,^=,4V[ED"*21$%")*)2E66=4FJE-*F=AVY*J[!HM*>@3TDR>QZ9Z=-53A
M!83+24;U-KJQPQ79T829E&SV**JD@@%2%8%9JI[ANDLB3$G9*4F9BHL\_KES
M]*Y3%7MP&*UO:ZIT\M;\\M,2=+NV"<#;UM$-'S)@K6#221(0:,C466HD )&$,R@ " 8,G:6A&5EYP(, , =1\_91C1U(2+ML
MP8,6R[Q\^>+)MF;)FU2.NY=NW*QB(MFK=%,QSJ',4A"E$1$ # &-TK<&@Z[0
M=NJ'K6DZS;,%B-GSFDZAB:C;LG"I#*)(/%H=V\3;+*IE$Q2G$HF ,PV8C4*K
MJI2AVZIK&D:%A7%25M5-.T=3K1=FV=3]534;3T(V
(^T>ZR/ZQKO"NW?SF?:@O=Z\8<+X9\.L'=X6H5+TO)58MHC\T1
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M"D(0@ 4A0 ##A?#/AU@[O"U#2WG>3)K1'VCW6=H>\;[PKMW\YGVH+W>O&
M'"V&?#K!W>%J&';SO)5GM,?:/]8_K&N\*[=_.7]J"]WKQB<+X9\.L'=X6H92
M]+SWF/M'^L?UC7>%=N_G,^U!>[UXQ>%\,^'6#N\+4-)>=Y-9^HC[1_K(_K&N
M\*[=_.9]J"]_KQAPOAGPZP=WA:AOYI>.\1]H]UC^L;[PKMX:"]WKQAPMAGPZP=WA:A?FEY-FM,=G[Q_K/O=
MW2/^\+5_;&KN!(ER*Y;XT%'X-O>C*MI>M$)S3B*Z\
MC'K/[SKST!("K^%$>1YJL^$);;5ER?U%>VO>4RD"LKX3O-'0W+U0-;%9RD]*
M\LL7>2T["MG5&0"#ML^;0E>2 "Y#TAGT[1#+I'&V-.I:R4I=!\ON>FJ*L:V!H&U$:
MTN7"45<6@JI^F&KZ#L?=NMI".MU2-ND#2%MCQMLZ6K,]L)BZD_,L8Y1[*K-F
M\9!-Y<4G NTT#DJUY4*D[)YE9]_WT4\FDN6"/HGF84Y1+87:H=&O+-6^[OJT
M==4A0-UK<3;*E)B\#11K;*NJR6I"X4*RC:S2I6E>!;0
U37%-2]/PLT6KH.&9T^